Clinical features, outcome and risk factors in cervical cancer patients after surgery for chronic radiation enteropathy

Radiat Oncol. 2015 Jun 6:10:128. doi: 10.1186/s13014-015-0433-5.

Abstract

Background: Radical hysterectomy and radiotherapy have long been mainstays of cervical cancer treatment. Early stage cervical cancer (FIGO stage IB1-IIA) is traditionally treated using radical surgery combined with radiotherapy, while locally advanced cervical cancer is treated using radiotherapy alone or chemoradiotherapy. In this retrospective study, we describe and analyse the presenting clinical features and outcomes in our cohort and evaluate possible risk factors for postoperative morbidity in women who underwent surgery for chronic radiation enteropathy (CRE).

Methods: One hundred sixty-six eligible cervical cancer patients who underwent surgery for CRE were retrospectively identified between September 2003 and July 2014 in a prospectively maintained database. Among them, 46 patients received radical radiotherapy (RRT) and 120 received radical surgery plus radiotherapy (RS + RT). Clinical features, postoperative morbidity and mortality, and risk factors for postoperative morbidity were analysed.

Results: RS + RT group patients were more likely to present with RTOG/EORTC grade III late morbidity (76.1 % vs 92.5 %; p = 0.004), while RRT group patients tended to show RTOG/EORTC grade IV late morbidity (23.9 % vs 7.5 %; p = 0.004). One hundred forty patients (84.3 %) were treated with aggressive resection (anastomosis 57.8 % and stoma 26.5 %). Overall and major morbidity, mortality and incidence of reoperation in the RRT and RS + RT groups did not differ significantly (63 % vs 64.2 % [p = 1.000], 21.7 % vs 11.7 % [p = 0.137], 6.5 % vs 0.8 % [p = 0.065] and 6.5 % vs 3.3 % [p = 0.360], respectively). However, incidence of permanent stoma and mortality during follow-up was higher in the RRT group than in the RS + RT group (44.2 % vs 12.6 % [p = 0.000] and 16.3 % vs 3.4 % [p = 0.004], respectively). In multivariate analysis, preoperative anaemia was significantly associated with overall morbidity (p = 0.015), while severe intra-abdominal adhesion (p = 0.017), ASA grades III-V (P = 0.022), and RTOG grade IV morbidity (P = 0.018) were predicators of major morbidity.

Conclusions: Radiation-induced late morbidity tended to be severe in the RRT group with more patients suffering RTOG/EORTC grade IV morbidity, while there were no significant differences in postoperative morbidity, mortality and reoperation. Aggressive resection was feasible with acceptable postoperative outcomes. Severe intra-abdominal adhesion, ASA grades III-V and RTOG/EORTC grade IV late morbidity contributed significantly to major postoperative morbidity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemoradiotherapy / adverse effects*
  • Colostomy / adverse effects
  • Colostomy / statistics & numerical data
  • Combined Modality Therapy
  • Comorbidity
  • Digestive System Surgical Procedures / adverse effects
  • Digestive System Surgical Procedures / statistics & numerical data*
  • Female
  • Follow-Up Studies
  • Humans
  • Hysterectomy
  • Ileostomy / adverse effects
  • Ileostomy / statistics & numerical data
  • Intestinal Diseases / epidemiology*
  • Intestinal Diseases / etiology
  • Intestinal Diseases / surgery
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / mortality
  • Neoplasm Recurrence, Local / surgery
  • Peritoneal Diseases / epidemiology
  • Peritoneal Diseases / etiology
  • Peritoneal Diseases / surgery
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Postoperative Complications / surgery
  • Radiation Injuries / epidemiology*
  • Radiation Injuries / etiology
  • Radiation Injuries / surgery
  • Radiotherapy, Adjuvant / adverse effects*
  • Reoperation
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Short Bowel Syndrome / etiology
  • Tissue Adhesions / epidemiology
  • Tissue Adhesions / etiology
  • Uterine Cervical Neoplasms / radiotherapy*
  • Uterine Cervical Neoplasms / therapy